ArticlePharmacoEconomics2015
Preferred Reporting Items for Studies Mapping onto Preference-Based Outcome Measures: The MAPS Statement.
Article in PharmacoEconomics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Deriving Health Utility Values Using Mapping Methods Among the Chinese Population: A Systematic Review.Applied health economics and health policy · 2026Pooled it
- A systematic review of crosswalks for converting patient-reported outcome measure scores in hip, knee, and shoulder replacement surgery.Acta orthopaedica · 2024Pooled it
- Quality appraisal for systematic literature reviews of health state utility values: a descriptive analysis.BMC medical research methodology · 2022Pooled it
- Mapping of the EORTC QLQ-LC43 to EQ-5D-5 L index in patients with lung cancer: comparison of traditional regression models with machine learning technique.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- Translating the EORTC CAT core and the QLQ-C30 to the EQ-5D-5L in patients with metastatic breast cancer: A comparison of direct and indirect mapping algorithms.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- The RETRIEVE Checklist for Studies Reporting the Elicitation of Stated Preferences for Child Health-Related Quality of Life.PharmacoEconomics · 2024Article
- Mapping the EQ-5D-5L from the Spanish national health survey functional disability scale through Bayesian networks.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2023Article
- Mapping the EORTC QLQ-C30 onto the EQ-5D-5L index for patients with paroxysmal nocturnal hemoglobinuria in France.Journal of comparative effectiveness research · 2023Article
- Mapping the Patient-Reported Outcomes Measurement Information System (PROMIS-29) to EQ-5D-5L.PharmacoEconomics · 2023Article
- An examination of machine learning to map non-preference based patient reported outcome measures to health state utility values.Health economics · 2022Article
- Adapting preference-based utility measures to capture the impact of cancer treatment-related symptoms.The European journal of health economics : HEPAC : health economics in prevention and care · 2021Article
- A Review of Utility Measurement Methods Used in Pharmacoeconomic Submissions to HIRA in South Korea: Methodological Consistency and Areas for Improvement.PharmacoEconomics · 2021Review
- Mapping PedsQL™ Generic Core Scales to EQ-5D-3L utility scores in transfusion-dependent thalassemia patients.The European journal of health economics : HEPAC : health economics in prevention and care · 2021Article
- Evaluating the conduct and application of health utility studies: a review of critical appraisal tools and reporting checklists.The European journal of health economics : HEPAC : health economics in prevention and care · 2021Review
- Does linear equating improve prediction in mapping? Crosswalking MacNew onto EQ-5D-5L value sets.The European journal of health economics : HEPAC : health economics in prevention and care · 2020Article
- Mapping the kidney disease quality of life 36-item short form survey (KDQOL-36) to the EQ-5D-3L and the EQ-5D-5L in patients undergoing dialysis.The European journal of health economics : HEPAC : health economics in prevention and care · 2019Article
- Assessment of outcome measures for cost-utility analysis in depression: mapping depression scales onto the EQ-5D-5L.BJPsych open · 2018Article
- Statistical Alchemy: Conceptual Validity and Mapping to Generate Health State Utility Values.PharmacoEconomics - open · 2017Article
- Mapping the SRS-22r questionnaire onto the EQ-5D-5L utility score in patients with adolescent idiopathic scoliosis.PloS one · 2017Article
- Using Linear Equating to Map PROMIS(®) Global Health Items and the PROMIS-29 V2.0 Profile Measure to the Health Utilities Index Mark 3.PharmacoEconomics · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
'Mapping' onto generic preference-based outcome measures is increasingly being used as a means of generating health utilities for use within health economic evaluations. Despite the publication of technical guides for the conduct of mapping research, guidance for the reporting of mapping studies is currently lacking. The MAPS (MApping onto Preference-based measures reporting Standards) statement is a new checklist, which aims to promote complete and transparent reporting of mapping studies. The primary audiences for the MAPS statement are researchers reporting mapping studies, the funders of the research, and peer reviewers and editors involved in assessing mapping studies for publication. A de novo list of 29 candidate reporting items and accompanying explanations was created by a working group comprising six health economists and one Delphi methodologist. Following a two-round modified Delphi survey with representatives from academia, consultancy, health technology assessment agencies and the biomedical journal editorial community, a final set of 23 items deemed essential for transparent reporting, and accompanying explanations, was developed. The items are contained in a user-friendly 23-item checklist. They are presented numerically and categorised within six sections, namely: (1) title and abstract; (2) introduction; (3) methods; (4) results; (5) discussion; and (6) other. The MAPS statement is best applied in conjunction with the accompanying MAPS explanation and elaboration document. It is anticipated that the MAPS statement will improve the clarity, transparency and completeness of reporting of mapping studies. To facilitate dissemination and uptake, the MAPS statement is being co-published by seven health economics and quality-of-life journals, and broader endorsement is encouraged. The MAPS working group plans to assess the need for an update of the reporting checklist in 5 years' time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.